glp 1 agonist cardiovascular outcomes Glucagon-like peptide receptor agonists: benefits and mechanisms of action An Observational Study of Cardiovascular
Description
GLP-1s are medications that mimic a natural hormone in the body that helps to regulate blood sugar levels and appetite
Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.
Designed to complement your GLP-1 journey
A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year
Adults with pulmonary arterial hypertension using vs
